MELVILLE, NY (Sept. 7, 2004) – Pharmaceutical manufacturer Fougera announced that Paul B. McGarty took over as chief executive officer, effective September 1. In the role, McGarty will oversee all functional areas of the company, including sales,marketing, business development, scientific, and manufacturing for Fougera andPharmaDerm, the company said.
McGarty has more than 20 years of industry experience in major pharmaceutical companies, including Bristol-Myers Squibb and American HomeProducts (Wyeth), as well as start-up experience as chief executive officer of Aesgen, Inc. (a Mayo Clinic venture).
He began his pharmaceutical career with a degree in chemical engineering from the University of Rhode Island and worked at American Cyanamid (Lederle Laboratories) for 13 years in a variety of management assignments in manufacturing, marketing, sales and business development. He earned his M.B.A. from Pace University in New York.
At Bristol-Myers Squibb he was director of World-Wide Franchise Management and most recently he was senior vice president of U.S. operations at Taro Pharmaceuticals.
Fougera is a specialty pharmaceutical manufacturer of topical steroids, antibiotics and antifungal products, as well as ophthalmics. PharmaDerm manufactures, acquires, licenses and markets pharmaceutical products in targeted markets within the United States. Fougera and PharmaDerm are divisions of Altana Inc.
